{
  "@context": "aku-v2",
  "@type": "treatment",
  "@id": "vasc:wound:skin-substitutes",
  "metadata": {
    "version": "2.0.0",
    "created": "2026-01-07T03:25:00.000Z",
    "updated": "2026-01-07T03:25:00.000Z",
    "contributors": ["knowledge-graph-agent"],
    "confidence": 0.88,
    "status": "pending-quality-check"
  },
  "classification": {
    "domain_path": "health-sciences/medicine/surgery/vascular/wound-care",
    "type": "advanced-therapy",
    "difficulty": "advanced",
    "importance": "moderate"
  },
  "content": {
    "title": "Skin Substitutes for Chronic Wounds",
    "description": "Bioengineered tissue products for wound coverage",
    "key_concepts": [
      {
        "concept": "Categories",
        "details": "Acellular matrices, cellular products, composite products"
      },
      {
        "concept": "Examples",
        "details": "Apligraf (bilayer), Dermagraft (dermal), OASIS (acellular matrix), Integra"
      },
      {
        "concept": "Indications",
        "details": "Chronic wounds failing to progress with standard care after 4 weeks"
      },
      {
        "concept": "Requirements",
        "details": "Adequate wound bed preparation, infection control, address underlying pathology"
      }
    ],
    "clinical_significance": "Advanced therapies for wounds refractory to standard treatment"
  },
  "provenance": {
    "primary_sources": ["Frykberg RG et al. Int Wound J 2015"]
  }
}
